Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM, et al
Reduction of insulin resistance (IR) and enhancement of insulin secretion IR is a primary factor affecting glucose metabolism and homeostasis in T2DM
typically dose-related and diminishing over time Serious risks : Pancreatitis (rare), gallbladder events, thyroid C-cell tumor boxed warning (from rodent studies) Dose escalation : Slow titration (0.25 mg escalating monthly) mitigates GI tolerability Strength : The safety database is massive, with well-defined risk-benefit profile across multiple patient populations Survodutide Side Effects# Less well-characterized with limited clinical exposure: GI effects : Expected GLP-1 class effects (nausea, vomiting, diarrhea) observed in Phase 2 Glucagon-specific concerns : Potential for hepatic glucose output increase (mitigated by GLP-1 component), theoretical impact on blood glucose in diabetic populations Heart rate : Glucagon receptor agonism may affect heart rate
Rather than forcing sedation, DSIP is believed to support the bodys natural ability to enter and maintain restorative sleep states
Maybe you're on a waiting list that seems endless
As GLP-1 therapy progresses and weight loss occurs, your provider may need to reduce or discontinue some antihypertensive medications to prevent symptomatic low blood pressure, but this decision requires medical supervision and regular blood pressure monitoring